

SPECIALTY GUIDELINE MANAGEMENT

ADAKVEO (crizanlizumab-tmca)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication

Adakveo is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL

Sickle cell disease, to reduce the frequency of vasoocclusive crises

Authorization of 12 months may be granted for use in reducing the frequency of vasoocclusive crises (VOCs) in members 16 years of age or older with sickle cell disease and prior vasoocclusive crises.

III. CONTINUATION OF THERAPY

Sickle cell disease, to reduce the frequency of vasoocclusive crises

Authorization of 12 months may be granted for continued treatment when the member has experienced a reduction in the frequency of vasoocclusive crises, or has maintained such reduction, since initiating therapy with Adakveo.

IV. REFERENCES

1. Adakveo [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; November 2019.
2. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. *N Engl J Med.* 2017;376(5):429-439.